SecBot SecBot

IMA

ImageneBio, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001835579 Biotech & Drug Discovery
$3.20 −0.27 (−7.78%)
Nov 16 4:00 PM ET · prev $3.47
Market cap
$43.2M
Nano cap
Consensus
Buy
75% Buy or better · 8 analysts
Median target
$24.00
+650% · range $2.00–28.00
1 year
−58.4%
from $7.70 · Nov 17
30 days
−20.0%
from $4.00
52-week range
$3.20–7.70
at the low
Avg volume 20D
11.6K
Oct 26 spike 32.9K
Short interest
46.0K
≈0.4% of shares · −25.1%
Days to cover
4.0
at average volume
Insider net
−$17.3K
2 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $17.3K.

  • InstitutionsMIXED

    Q3 2026: 2 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    6 of 8 rate it Buy or better. Median target $24.00 (+650%).

  • EstimatesRISING

    Current-quarter EPS estimate −$1.235 → −$0.847 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −25.1% to 46.0K shares. 4.0 days to cover, ≈0.4% of shares.

  • TrendDOWNTREND

    27% below its 50-day average. New closing low $3.20 on Nov 16.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 7.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCADD67,537$309.3K
VANGUARD FIDUCIARY TRUST COADD49,261$225.6K
MORGAN STANLEYTRIM9,166$42.0K
CITADEL ADVISORS LLCTRIM55,610$328.1K
GOLDMAN SACHS GROUP INCADD15,485$91.4K
UBS Group AGADD6,879$40.6K
JPMORGAN CHASE & CONEAR_EXIT70$425.00
JACOBS LEVY EQUITY MANAGEMENT, INCADD26,663$133.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 75% rate it Buy or better
Strong Buy3Buy3Hold1Sell0Strong Sell1
12-month targets · 3 analysts

Price is inside the target range. Median implies +650%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 21, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 2 insiders
$17.3K
sold · 1 insider
DateInsiderTypeValue
Aug 14, 2026
Yarema Kristin
Chief Executive Officer
Aug 14, 2026
AWARD137,200 sh
Aug 14, 2026
Yarema Kristin
Chief Executive Officer
Aug 14, 2026
AWARD254,800 sh
Aug 14, 2026
Yarema Kristin
Chief Executive Officer
Aug 14, 2026
AWARD250,000 sh
Aug 14, 2026
Grant-Huerta Yanina
Chief Financial Officer
Aug 14, 2026
AWARD65,000 sh
Aug 14, 2026
Grant-Huerta Yanina
Chief Financial Officer
Aug 14, 2026
AWARD39,000 sh
Aug 14, 2026
Grant-Huerta Yanina
Chief Financial Officer
Aug 14, 2026
AWARD56,000 sh
Jul 25, 2026
Yarema Kristin
Chief Executive Officer
Jul 25, 2026
EXERCISE38,376 sh
Jul 25, 2026
Yarema Kristin
Chief Executive Officer
Jul 25, 2026
OTHER115,129 sh

Earnings setup

Estimates
−$0.85
EPS estimate, this quarter
+31%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.85-$0.98–-$0.72+31.4%$0.00
Next Q-$0.91-$0.91–-$0.91+14.6%$0.00
Current FY-$3.37-$3.55–-$3.08-1.8%$0.00
Next FY-$3.36-$5.73–-$0.66+22.0%$0.00

Short side

FINRA· Oct 30, 2026
45,958
shares short
-25.1%
vs prior settlement
4.0
days to cover
≈0.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Blue Owl Capital Holdings LP filed an amended Schedule 13G disclosing beneficial ownership of 1,135,081 shares of…
SC 13G/A · Impact 2/10
Nov 10, 2026 Earnings calendar
IMA Q3 2026 Earnings After Market Close · 2026-11-10
Nov 9, 2026 SEC
ImageneBio reported Q3 2026 net loss of $15.6M ($0.91 per share), narrower than the $24.8M loss ($2.91 per share) in…
8-K · Impact 4/10
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · ADD
67,537 shares ($309.3K)
Sep 30, 2026 Inst.
VANGUARD FIDUCIARY TRUST CO · ADD
49,261 shares ($225.6K)
Aug 14, 2026 Insider
Yarema Kristin was granted 137,200 shares
Chief Executive Officer
Aug 14, 2026 Insider
Yarema Kristin was granted 254,800 shares
Chief Executive Officer
Aug 14, 2026 Insider
Yarema Kristin was granted 250,000 shares
Chief Executive Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 10, 2026
Earnings date
IMA Q3 2026 Earnings After Market Close · 2026-11-10
Oct 2, 2026
Press release
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026…
Sep 8, 2026
Press release
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive…
Aug 5, 2026
Earnings
ImageneBio Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the…
Jul 22, 2026
Earnings date
IMA Q2 2026 Earnings After Market Close, 2026-07-22

SecBot reports

7 filings · 3 press releases · 0 bullish · 2 bearish · 5 neutral
All IMA filing & press-release reports (10)